Stock Analysis

Postmedia Network Canada Full Year 2024 Earnings: CA$0.50 loss per share (vs CA$0.73 loss in FY 2023)

TSX:PNC.B
Source: Shutterstock

Postmedia Network Canada (TSE:PNC.B) Full Year 2024 Results

Key Financial Results

  • Revenue: CA$395.9m (down 12% from FY 2023).
  • Net loss: CA$49.7m (loss narrowed by 32% from FY 2023).
  • CA$0.50 loss per share (improved from CA$0.73 loss in FY 2023).
earnings-and-revenue-history
TSX:PNC.B Earnings and Revenue History November 23rd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Postmedia Network Canada shares are down 12% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 5 warning signs for Postmedia Network Canada you should be aware of, and 4 of them can't be ignored.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSX:PNC.B

Postmedia Network Canada

Through its subsidiary, engages in publishing daily and non-daily newspapers in Canada.

Moderate and slightly overvalued.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor